Leaders in BioBanking Congress 2015 - 2015生物資料庫學會 -
2015年7月14 - 16日
加拿大,安大略省,多倫多,多倫多中心洲際酒店

目前生物檢體的採集由各種研究團體所進行,其目的亦包括從基礎研究到臨床實驗。對高品質的生物學研究而言,完善管理的生物資料庫是不可或缺的。此外,適當的生物檢體採樣、處理、保存及追蹤,為研究人員以更佳形式結合分子資訊與臨床資訊上非常重要的因素。因此,生物資料庫可說是與科學及商業雙方面息息相關。

Cambridge Healthtech Institute (CHI)舉辦的第7屆International Leaders in Biobanking Congress: Maximizing Your Investment in Biospecimens,為聚焦生物資料庫在科學及商業兩個層面的學會。會期中將邀集生物醫學和生物醫藥品的研究人員、法規當局、生物檢體入出庫管理者及實務人員等,探討在現今最尖端研究的生物醫學研究上如何有效利用生物檢體的最佳策略。


會前短期課程 | 第1天 | 第2天 | 第3天 | 會後會 | 演講者


7月13日(一)

1:00 pm 短期課程報到登記


1:30-5:30 會前短期課程*

* 敬請個別報名參加


5:00 主會議報到登記


研究設施實地考察與交流晚會:University Health Network (UHN)的生物檢體研究計畫

(參加人數以50名為限)

6:00-8:00

5:45 搭乘研究設施實地考察接駁車

* 免費提供往返Intercontinental Toronto Centre與研究設施的接駁車服務。

6:00-8:00 實地考察與交流晚會:UHN的生物檢體研究計畫

This tour at Canada's largest academic hospital system begins in surgical pathology with the banking of complex surgical specimens and data entry into our customized caTissueSuite research specimen management system. The tour continues to our laboratories for a demonstration of our state-of-the-art biospecimen information technology system, digital image analysis and laser capture microdissection.

8:00 搭乘接駁車返回飯店

8:15 會前短期課程結束


會前短期課程 | 第1天 | 第2天 | 第3天 | 會後會 | 演講者


7:30 am 7月14日(二)

7:30 am 主會議報到登記與晨間咖啡


專題講習:做為社區整體所必須的作為

8:00 歡迎致詞與議長開會引言

Michael RoehrlMichael H. A. Roehrl, M.D., Ph.D., Director, UHN Program in BioSpecimen Sciences, University Health Network and University of Toronto

8:15 病理學者做為生物檢體管理者所承擔責任的複雜度

Sylvia AsaSylvia L. Asa, M.D., Ph.D., Pathologist-in-Chief, Medical Director, Laboratory Medicine Program, University Health Network; Lakeridge Health & Women's College Hospital; Senior Scientist, Ontario Cancer Institute; Professor, Laboratory Medicine & Pathobiology, University of Toronto

Pathologists have responsibility for handling patient biospecimens; they implement rigorous quality assurance of processes that determine how specimens are collected, processed, examined, reported and either destroyed, biobanked or retained on file. Pathology is ideally positioned to develop and oversee biobanks and because of its capacity for data generation, generally provides the greatest amount of information for specimen annotation. Pathology also is subject to mandatory requirements for retention of clinical records, including tissue blocks and slides, for legal and accreditation purposes, emphasizing the importance of collecting and documenting biospecimens for research.

9:00 使用與電子健康紀錄(EHR)連動的生物資料庫之發現與執行:eMERGE的經驗

Rex ChisholmRex L. Chisholm, Ph.D., Vice Dean, Scientific Affairs and Graduate Education; Adam and Richard T. Lind Professor, Medical Genetics, Northwestern University Feinberg School of Medicine

Biobanks linked to electronic health records (EHR) provide a unique opportunity to study the association between genetic variation and phenotypes. The eMERGE network, funded by the National Human Genome Research Institute, has not only demonstrated the utility of this approach, but has also begun to develop methods for associating specific genomic variants with EHRs and providing clinical decision support to assist care providers in the use of this information.

9:45 休息時間

10:15 未來使用之研究樣品的製備:因應功能性品質管理評價的創新手法與生物資料庫的最佳實務

Andrew BrooksAndrew Brooks, Ph.D., COO, RUCDR Infinite Biologics; Associate Professor, Genetics, Rutgers University

The presentation focuses on biomarker development and translational research optimization by taking into account how samples are collected, selection of the best technology for sample bioprocessing, global biobanking best practices and how information on each sample should be stored to enhance data sharing throughout the research process. Specific topics to be discussed include:

  • Sample bioprocessing and quality control methods that maximize the utility of collected biospecimens for current and future research
  • Understanding the power of evolving genomic technologies and how to develop a sample-centric roadmap for future research use
  • The role of centralized biobanking and global data integration in real-time data mining and optimization of biospecimen resources
  • How to build scientific and operational biomarker development synergies through collaborations to increase research productivity

11:00 生物檢體入出庫網絡的綜合標準作業程序的制定-CTRNet的經驗

Brent SchacterBrent Schacter, M.D., FRCPC, Principal Investigator, CTRNet; Professor, Department of Internal Medicine, Section of Hematology/Oncology, College of Medicine, University of Manitoba/CancerCare Manitoba

The Canadian Tissue Repository Network is a consortium of Canadian tumour biorepositories that aims to enhance biobanking capacity and quality through standardization. To minimize the issue of variable biobanking practices, CTRNet has developed and maintained a comprehensive set of standard operating procedures (SOPs). The key elements of the CTRNet SOP development process will be described. Once developed, reviewed and ratified by CTRNet, the SOPs have been published on our website for public access (with over 15,000 downloads in over 60 countries).

11:45 講習結束

12:00 pm 午餐會簡報(贊助商招募中)或各自享用午餐


高品質生物資料庫的維持

2:00 議長引言

Andrew BrooksAndrew Brooks, Ph.D., COO, RUCDR Infinite Biologics; Associate Professor, Genetics, Rutgers University

2:05 社區醫院系統的全國生物檢體採集網絡之建立與執行

Jeffrey OttoJeffrey Otto, MBA, Ph.D., National Director, Center for Translational Research, Institute for Research and Innovation, Catholic Health Initiatives

Catholic Health Initiatives is the fifth-largest health system in the U.S., with 100+ hospitals spread nationally. Within this community hospital system, the Center for Translational Research (CTR) has built a first-of-its-kind hub-and-spoke biorepository program. Key attributes of this biorepository include: 1) high physical biospecimen quality, 2) EMR-linked patient data, and 3) full chain of custody. This presentation discusses how this program was built.

2:35 庫存管理:生物檢體入出庫的重整、整理統合、品質確保、空間成本

Sherilyn SawyerSherilyn J. Sawyer, Ph.D., Director, BWH/Harvard Cohorts Biorepository, Channing Division of Network Medicine, Brigham and Women's Hospital

Space and organization within the available space are two high-level concerns of the biorepository. We have recently undertaken a multiyear project to reorganize inventory in order to recover lost space and utilize space more efficiently. A cost/benefit analysis of this project contributes to understanding the true costs of space for biorepositories.

3:05 贊助商簡報

Speaker to be Announced

3:20 贊助商簡報

3:35 展示會場休息與論文海報鑑賞

4:00 針對受試者同意的課題以及老舊生物資料庫檢體的再同意之Web型解決方案

Daniel ThielDaniel B. Thiel, Public Health Researcher, Health Services Organization and Policy, University of Michigan School of Public Health

Highlighting the results of a pilot web-based informed consent portal for legacy donors to the Michigan BioTrust for Health, this presentation explores practical and ethical challenges raised by informed consent for legacy donors to biobanks. In the case of Michigan's BioTrust, the legacy samples are residual dried bloodspots derived from state-mandated newborn screening. I also consider this experiment in light of broader implications for biobanks comprising legacy samples.

4:30 組織庫、生物資訊學、電子病歷系統(EMR):個人化醫療的前提條件

K. Stephen SuhK. Stephen Suh, Ph.D., Director, Genomics and Biomarkers Program, John Theurer Cancer Center, Hackensack University Medical Center

Personalized medicine promises patient-tailored treatments that enhance patient care and decrease overall treatment costs by focusing on genetics and "-omics" data obtained from patient biospecimens and records to guide therapy choices that generate good clinical outcomes. The approach relies on diagnostic and prognostic use of novel biomarkers discovered through combinations of tissue banking, bioinformatics and electronic medical records (EMRs).

5:00 座談會:透過有效使用以確保生物資料庫的價值

Biobanks are necessary and expensive research infrastructures. The ability to demonstrate effective utilization of biobanks is a quality measure that is essential for both financial and social sustainability. This panel discusses approaches for effective utilization of specimens from biobanks, both in the establishment of new biobanks and in the use of legacy collections.

Moderators:

Marianne-HendersonMarianne K. Henderson, MS, CPC, Chief, Division of Cancer Epidemiology & Genetics, Office of Division Operations and Analysis and the Center for Global Health, National Cancer Institute; Chair, Organizing Advisory Committee, ISBER



Marianna BledsoeMarianna J. Bledsoe, MA, Adjunct Assistant Professor, Department of Clinical Research and Leadership, George Washington University School of Medicine and Health Sciences; Co-Chair, Science Policy Committee, ISBER

Panelists:

Jeffrey OttoJeffrey Otto, MBA, Ph.D., National Director, Center for Translational Research, Institute for Research and Innovation, Catholic Health Initiatives

Sherilyn SawyerSherilyn J. Sawyer, Ph.D., Director, BWH/Harvard Cohorts Biorepository, Channing Division of Network Medicine, Brigham and Women's Hospital

K. Stephen SuhK. Stephen Suh, Ph.D., Director, Genomics and Biomarkers Program, John Theurer Cancer Center, Hackensack University Medical Center

Daniel ThielDaniel B. Thiel, Public Health Researcher, Health Services Organization and Policy, University of Michigan School of Public Health

Additional Panelists to be Announced

6:00 展示會場歡迎晚會與論文海報鑑賞

7:00 第1天結束


會前短期課程 | 第1天 | 第2天 | 第3天 | 會後會 | 演講者


7月15日(三)

7:30 am 早餐會簡報(贊助商招募中)或晨間咖啡

8:00 生物資料庫腦力激盪:為早餐會小組討論

咖啡小組討論。本討論會是以參加者交換意見、探討問題解決對策的形式進行,來自不同背景的參加者針對焦點議題發表各自的想法和經驗,並發展未來的合作關係。

品質系統-生物資料庫所有要素所依據的脈絡

Michael BreardMichael Breard, MS, MT(ASCP)SBB, CQA(ASQ), PMP(PMI), Vice President, Consulting Services and Sale, AABB

  • What is a quality system?
  • Why is quality important?
  • How do you achieve quality?
  • Is quality expensive?
  • What does it take to reach your quality goal?

Inventory Management and Data Annotation

Rajiv Dhir, M.D., MBA, Chief, Pathology, Shadyside Hospital, University of Pittsburgh Health Systems

  • What is inventory management and how do you currently address your needs?
  • What are the most common problems you have with inventory management?
  • What are the most common data annotation needs seen by you and how do you address them?
  • How do you provide data to your clients/investigators? Do you utilize honest brokers?

生物檢體、生物標記、臨床試驗

9:00 議長引言

Jeffrey OttoJeffrey Otto, MBA, Ph.D., National Director, Center for Translational Research, Institute for Research and Innovation, Catholic Health Initiatives

9:05 特別演講:透過臨床試驗將精確醫療策略轉化成結果

Lillian SiuLillian L. Siu, M.D., FRCPC, Professor, University of Toronto; Medical Oncologist, Princess Margaret Cancer Centre

Clinical trial frameworks focusing on interpatient heterogeneity include histology-based trials to evaluate therapeutic targeting of different molecular aberrations harbored by patients with a single tumor type ("umbrella trials"); as well as those that are histology-agnostic, aberrationspecific to encompass the assessment of similar molecular changes across different tumor types ("basket trials"). In this presentation, the benefits and challenges of genomics-based clinical trials are discussed, including a forecast into the next-generation precision medicine-based clinical research.


9:35 多中心型淋巴瘤臨床試驗的相關研究上的生物檢體調度

Koren MannKoren Mann, Ph.D., Assistant Professor, Oncology, Lady Davis Institute for Medical Research, McGill University

To develop novel agents in lymphoma, we must understand the molecular changes induced by these drugs, particularly in the context of clinical trials. We have developed a series of standard operating procedures (SOPs) to collect quality biospecimens for multiple downstream applications, including immunohistochemistry, exome sequencing, gene expression profiling, metabolomics and circulating tumor DNA. These SOPs were then validated in the context of the Q-CROC2 trial testing the efficacy of the histone deacetylase inhibitor, panobinostat, +/- rituximab in diffuse large B-cell lymphoma.

10:05 贊助商簡報

10:35 展示會場休息與論文海報鑑賞

11:15 個案研究#1:生物檢體科學、臨床試驗、精確醫療:實務案例

Michael RoehrlMichael H. A. Roehrl, M.D., Ph.D., Director, UHN Program in BioSpecimen Sciences, University Health Network and University of Toronto

Anthony JoshuaAnthony M. Joshua, MBBS, Ph.D., Staff Oncologist/Affiliate Scientist, Princess Margaret Cancer Centre

We discuss the use of human biospecimens for translational research, in particular molecularly driven clinical trials and our Rapid Autopsy Program. We discuss optimal collection, use and quality of samples, patient enrollment and consent, and integrated clinical and research data collection and annotation.

12:00 pm 講習結束

12:15 午餐會簡報(贊助商招募中)或各自享用午餐


評價生物檢體品質的手段

2:00 議長引言

Galen-HostetterGalen Hostetter, M.D., FCAP, Associate Director, Pathology Core, Van Andel Research Institute





2:05 從研究階段到臨床階段:(前)解析變數與分析平台

Veronique NeumeisterVeronique Neumeister, M.D., Laboratory Director, Specialized Translational Services Lab, Department of Pathology, Yale University School of Medicine

Companion diagnostic tests are critically dependent on tissue quality. However, tissue handling and processing are not always tightly controlled and pre-analytical variables can significantly alter tissue quality. This presentation focuses on the effects of (pre-)analytical variables in the diagnostic and research setting. Methodology and importance of quality control, optimization and standardization of tissue processing, biomarker validation and development of useful laboratory tests for the clinical setting will be discussed.

2:30 成為人體生物資料庫參考的實驗動物模型

Galen-HostetterGalen Hostetter, M.D., FCAP, Associate Director, Pathology Core, Van Andel Research Institute

Experimental animal models have been widely used to inform veterinary and human pathophysiology with associated improved control of pre-analytic variables to include single marker QC probes or next-generation genomic sequencing of disaggregated tissue samples. We demonstrate animal experiments to combine tissue morphology and expressed protein by IHC, qualitative/quantitative measures of nucleic acids by RIN and Q-ratios, respectively, to assess effect of pre-analytic variables and provide the basis for standardized methods in tissue sample collection and processing.

2:55 加壓冷凍:冷凍保存的新手法

Nickolas GreerNickolas Greer, CSO, Rissali LLC

Chemical cryoprotectants are toxic to live cells, tissues and organs. Cryoprotectant toxicity increases with concentration. Both hydraulic pressure and cryoprotectants increase viscosity of aqueous solutions at the freezing point, inhibit ice crystal growth and induce vitrification of water. By applying pressure during freezing it may be possible to reduce concentration or eliminate cryoprotectants for preservation of viable biological materials, thereby solving the cryoprotectant toxicity problem.

3:20 血液銀行所使用變性加工解決方案以收集及保存紅色細胞的微流體裝置評價

Dana SpenceDana Spence, Ph.D., Associate Professor, Department of Chemistry, Michigan State University

The collection and storage solutions used to process erythrocytes for storage in transfusion medicine contain levels of glucose that are nearly 10-15x higher than that found in the circulation of a healthy human. Here, data is presented demonstrating that maintenance of normoglycemic levels during the blood storage process helps to maintain certain properties of the stored cells, even beyond five weeks in storage.

3:45 贊助商簡報

4:15 展示會場休息與論文海報鑑賞


4:50 特別演講:影響因應多設施共同研究下免疫監測的末梢血液樣本的解析前變數

Amit Bar-OrAmit Bar-Or, M.D., FRCPC, Professor, Neurology & Neurosurgery; Director, Experimental Therapeutics Program and Scientific Director, Clinical Research Unit, Montreal Neurological Institute, McGill University

While there has been rapid growth in multicenter biomarker-development and immune-monitoring initiatives, including a major investment in procuring biological samples for cell-based assays, relatively little has been done to formally assess the impact of pre-analytical variables on functional immune responses within such samples. This presentation considers the impact of shipping approach and ambient temperature on such readouts.



個案研究:生物資料庫與使用者的合作

Biomedical researchers and drug developers require accessible, highquality biospecimens that allow them to extract reliable and useful data. Oncology experts, for instance, use patient-derived tumor collections to connect datasets, pinpoint and assess variants within cancer patients post-diagnosis and zero in on the data that matter when tailoring therapies. Early, strategic collaborations with the biobanks that house specimens can be mutually beneficial, maximizing the financial and technological investments of the operation managers who collect, store, annotate and distribute the biological samples ("biobankers") and supporting the research goals of the scientists who need those samples ("biousers") - all to fulfill the promise of personalized medicine.


5:15 個案研究#2

6:00 講習結束

6:00 短期課程報到登記晚餐


6:15-9:30 短期課程*

* 敬請個別報名參加


會前短期課程 | 第1天 | 第2天 | 第3天 | 會後會 | 演講者


7月16日(四)

7:30 am 早餐會簡報(贊助商招募中)或晨間咖啡


鎖定專門領域的生物資料庫

8:00 議長引言

Marianna BledsoeMarianna J. Bledsoe, MA, Adjunct Assistant Professor, Department of Clinical Research and Leadership, George Washington University School of Medicine and Health Sciences; Co-Chair, Science Policy Committee, ISBER

8:05 iPS細胞生物資料庫的未來

Jonathan Y.H. LohJonathan Y.H. Loh, Ph.D., Assistant Professor, Department of Biological Sciences, National University of Singapore, A*STAR Institute of Molecular and Cell Biology

We have developed the technology for efficient derivation of transgene-free hiPSCs from human finger-prick blood. Finger-prick sample collection can be performed on a "do-it-yourself" basis by donors and sent to the hiPSC facility for reprogramming. We show that single-drop volumes of finger-prick samples are sufficient for performing cellular reprogramming, DNA sequencing, and blood serotyping in parallel. Our novel strategy has the potential to facilitate the development of large-scale hiPSC banking worldwide.

8:35 以改善心臟移植結果為目的的生物資料庫

Dawn BowlesDawn E. Bowles, Ph.D., Assistant Professor, Department of Surgery, Division of Surgical Sciences and Co-Director, Duke Human Heart Repository

A human cardiac transplant biorepository for research on improving cardiac transplantation outcomes has been established. Evidence indicates an association between the levels of cardiac injury biomarkers in the preservation/transportation fluid from the donor heart of transplant cases and the development of inadequate cardiac function post-implant in the recipient. Continued evaluation of the preservation fluid will lead to better understanding of preservation injury and optimization of preservation/transport solutions for cardiac transplant.

9:05 針對兒童與婦女的制度化醫院的計畫立案與執行:倫理面與經營面的課題

Suzanne VercauterenSuzanne Vercauteren, M.D., Ph.D., FRCPC, Head, Division of Hematopathology, BC Children's Hospital and Clinical Assistant Professor, Pathology and Laboratory Medicine, University of British Columbia

The BCCH BioBank's goal is to ethically collect biospecimens and clinical data from pediatric and adult patients with a range of conditions and store them systematically for future research. Its founding principles include public engagement, long-term sustainability and high-quality specimens. Its planning and implementation was a complex process that involved detailed consideration of the ethical issues concerning the different types of potential participants and careful consideration of the operational structure of the biobank.

9:35 贊助商簡報

10:05 展示會場休息與論文海報鑑賞

10:45 University Health Network (UHN)的泌尿生殖器生物資料庫

Neil FleshnerNeil Fleshner, M.D., MPH, FRCSC, Chair, Urology, Department of Surgery, University of Toronto; Head, Urology, University Health Network; Director, GU BioBank, Princess Margaret Cancer Centre

The GU (genitourinary) BioBank is a predominantly bio-fluid-based program that follows consenting GU oncology participants over time, obtaining additional specimens and data at predefined intervals and upon any change in clinical state. This capacity for frequent and long-term follow-up has been made possible by integrating the BioBanking process with clinical care at UHN. The GU BioBank has garnered an incredible amount of interest in recent years. We share our experience in setting up and maintaining this patient-centered research program.

11:15 個案研究#3(贊助商招募中)

12:00 pm 講習結束

12:15 午餐會簡報(贊助商招募中)或各自享用午餐


鎖定專門領域的生物資料庫(接續)

2:00 議長引言

Marianne-HendersonMarianne K. Henderson, MS, CPC, Chief, Division of Cancer Epidemiology & Genetics, Office of Division Operations and Analysis and the Center for Global Health, National Cancer Institute; Chair, Organizing Advisory Committee, ISBER



2:05 加拿大國立臍帶血銀行概要

Heidi ElmoazzenHeidi Elmoazzen, Ph.D., Director, National Public Cord Blood Bank

Canadian Blood Services is building a National Public Cord Blood Bank which consists of five collection sites in four cities: Ottawa, Brampton, Edmonton and Vancouver, as well as two manufacturing facilities in Ottawa and Edmonton. An overview of the sources and use of hematopoietic stem cells as well as an overview of cord blood processing, cryopreservation and storage will be provided.

2:35 多倫多肺臟移植生物資料庫計畫所採集的檢體

Sassan AzadSassan M. Azad, Project Manager, Clinical, Translational & Biobanking Research Office, Toronto Lung Transplant Program, Toronto General Hospital, University Health Network

The Toronto Lung Transplant Program, one of the world's largest, is supporting clinical research in end-stage lung disease and advancing lung transplantation. Two major areas that limit successful application of lung transplantation are ischemia reperfusion injury (IRI) and bronchiolitis obliterans (BO). Our work explores underlying mechanisms of both these injuries and the development of therapeutic strategies to prevent or reverse them. Our current research focus is on biomarker discovery and gene therapy in lung transplantation.

3:05 休息時間,展示會與論文海報鑑賞的最後機會


利用IT以維持高品質的生物資料庫

4:15 可擴充研究資料庫的臨床資料及生物檢體入出庫資料收集的進展

Maureen E. Lane, Ph.D., Assistant Professor, Medicine; Director, Hem/Onc Translational Core Laboratory, The Leukemia Biorepository and Personalized Medicine Center, Weill Cornell Medical College

The Leukemia group at Weill Cornell Medical Center has been working with our information technology services (ITS) group to develop a Research Data Repository (RDR) that marries relevant clinical data with samples from our AML biorepository. This project is one of three pilot projects with a focus on supporting Precision Medicine and translational research at Weill Cornell.

4:40 因應轉譯研究與基礎研究的資料庫與生物檢體入出庫

Annmarie NowakAnnmarie Nowak, Coordinator & Director, Data Bank and Biorepository, Biobanking Systems Integration Cancer Prevention and Population Science, Roswell Park Cancer Institute

The Data Bank and BioRepository (DBBR) at Roswell Park Cancer Institute is a comprehensive data and sample bank, with biospecimens, epidemiologic and clinical information for investigators conducting translational research related to cancer prevention, etiology, detection and treatment. We discuss our recruitment, procurement and processing procedures, the structure and function of LIMS and the integration of clinical, research and biospecimen data.

5:05 高品質生物資料庫的實現與因應生物資料庫品質提升的作為:CRIP ToolBox與元生物資料庫架構p-BioSPRE

Christina SchröderChristina Schröder, Ph.D., Head, Metabiobanks CRIP, Fraunhofer Institute for Cell Therapy and Immunology

While biobank registries and catalogs will at best allow queries for specific biobank collections or cohorts, trans-institutional metabiobanks enable parameterized, stratified, though privacy-preserving queries in connected biobanks on a case-by-case and sample-by-sample basis. Building such metabiobanks for a decade, and drawing upon broad expertise in semantic data integration across sectors relevant for translational biomedical research, we have developed the metabiobank software suite "CRIP Toolbox". We showcase p-BioSPRE, the metabiobank setup for the EU FP 7-funded project p-medicine, as a multipurpose tool to internationally access and promote quality biobanks online.

5:30 學會結束


會前短期課程 | 第1天 | 第2天 | 第3天 | 會後會 | 演講者


會後活動

7月17日(五)


因應生物資料庫研究的受試者同意的內容與手續要件*

8:30 am-5:00 pm



This course presents the elements of the informed consent document and the components of the process, specifically as they relate to biobanking studies.

Instructor: Elizabeth Ronk Nelson, MPH, Barnett International


Participants will receive 7 hours (0.7 CEUs) from Accreditation Council for Pharmacy Education for full participation. For further information please visit barnettinternational.com

* 敬請個別報名參加



會前短期課程 | 第1天 | 第2天 | 第3天 | 會後會 | 演講者

* 活動內容有可能不事先告知作更動及調整。

Choose your language
Chinese
Japanese
Korean
English

Co-Hosted by
University Health Network logo

» 媒體合作夥伴

Catalog

產業會議彙總曆
免費電子郵件通知服務
免費電子郵件通知服務